Hematopoiesis is a complex, highly coordinated process in which proper function of cell-lineage and stage-specific gene regulation required in order to instruct stem cells to undergo self-renewal or adopt specific cell fates, and dysregulation of this process results in development of diseases such as Acute Myeloid Leukemia (AML). Transcription factors such as CCAAT Enhancer Binding Protein ? (C/EBPa) have been identified by our laboratory and others as playing a critical role in this process. Recently, a number of reports have Implicated epigenetic modifications, including histone acetylation, in normal hematopoiesis and leukemogenels. In this project, we will study the role of lysine acetyltransferases (KATs) In these processes, both with respect to their effects on C/EBPa, as well as on other targets. Including histones. These studies will lead to new understanding of how tissue-specific and lineage-specific gene expression is controlled through acetylation. Furthermore, since KATs work through an enzymatic activity, such studies may lead to development of new therapeutic approaches in AML. Therefore, the Specific Aims are:
Aim 1 : To investigate the role of acetylation of C/EBPa in granulopoiesis: In this aim, we will investigate how the transcription factor C/EBPa can be negatively or positively affected by GCN5 and TIP60 signaling pathways, respectively, at the post-translational level. We will specifically identify the site(s) acetylated by GCN5 and TIP60, and determine if C/EBPa acetylation is a stage or lineage(s) specific phenomenon. Our initial study suggests that GCN5 might represent a potential drug target for restoring C/EBPa function.
Aim 2 : To understand the role of two key epigenetic enzymes, the lysine acetyltransferases GCN5 and TIP60, in hematopoiesis and leukemia: Our studies will bridge between vast existing biochemical data on GCN5 and TIP60 acetylases and chromatin remodeling activities to their in-vivo functions in hematopoiesis. Furthermore, our studies will answer the question whether GCN5 or TIP60 are indispensable for hematopoietic stem cell (HSC) function. This project will interact with most of the other projects in this program, including investigating the interactions of acetyltransferases and their inhibition on BHS profiles (Project 1) and inhibitors of chromodomain proteins (Project 4). In addition, the project will utilize Core B for leukemic samples used in the project, as well as depend on biostatistic support (Core C). The ultimate aim is to develop new therapies based on these studies.

Public Health Relevance

Expected outcome: Our studies have the potential to uncover novel reversible C/EBPa protein modifications that could be directly relevant to leukemogenesis, and therefore help develop targeted therapies. Our studies on loss of function of GCN5 and TIP60 will underscore the role of these acetyltransferases in hematopoiesis and leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-16A1
Application #
8666230
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
1997-04-25
Project End
2019-08-31
Budget Start
2014-09-16
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$382,580
Indirect Cost
$54,310
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17

Showing the most recent 10 out of 376 publications